Supplementary Figure S4 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Key Points

• Findings reveal that lag-3+cd8+ subgroups are present in both treatment arms, highlighting potential immune responses.
• Prevalence data indicates a distinct distribution of lag-3+cd8+ among patients undergoing different treatments.
• Analysis utilized biomarkers to assess T-cell subsets in relation to relatlimab and nivolumab therapies.
• Understanding these subgroup dynamics may inform future therapeutic strategies for advanced melanoma cases.